> Physiology > Organism Function > Immune Reconstitution

Immune Reconstitution

Immune Reconstitution is the process of restoring the immune system's functionality after depletion or dysfunction, often observed in conditions like HIV/AIDS, cancer treatments, or organ transplantation.
This critical biological process involves the repopulation and reactivation of various immune cells, such as T cells, B cells, and natural killer cells, to re-establish the body's defense mechanisms.
Understanding the mechanisms and dynamics of immune reconstitution is crucial for developing effective therapies and improving patient outcomes in a wide range of medical scenarios.
Researchers can leverage PubCompare.ai's advanced AI-powered tools to streamline their quest for the optimal research protocols and products, accelerating discoveries and advancing the field of imrpoving immune reconstitution.

Most cited protocols related to «Immune Reconstitution»

Retrospective Analysis of SCID Patients

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013

Diagnosis Eligibility Determination Ethics Committees, Research Feelings Genotype HLA Typing Immune Reconstitution Patients SCID Mice Tissue Donors

Randomized Phase 3 Trial of Allogeneic Transplantation

The study was an open-label, phase 3, multicenter, randomized trial conducted by the Blood and Marrow Transplant Clinical Trials Network. Randomization was performed in a 1:1 ratio, with the use of random block sizes, and was stratified according to transplantation center and disease risk. The target enrollment was 550 donor–recipient pairs. The primary end point was 2-year survival as assessed by means of an intention-to-treat analysis. Prespecified secondary end points included post-transplantation incidences of neutrophil and platelet engraftment, graft failure, acute and chronic GVHD, relapse, and infections. Other end points included adverse events, immune reconstitution, time to discontinuation of immunosuppressive therapy, and quality of life. This article focuses on the primary end point and clinical secondary end points. Analyses of immune reconstitution and quality of life are ongoing.
Enrollment began on March 31, 2004, and ended on September 9, 2009. The analysis included data collected as of November 15, 2011. The median follow-up of surviving patients is 36 months (interquartile range, 30 to 37). Patients were followed in the study for 3 years, with a late analysis at 5 years planned with the use of data from the Center for International Blood and Marrow Transplant Research, which tracks the outcomes of all allogeneic transplantations in the United States.

Anasetti C., Logan B.R., Lee S.J., Waller E.K., Weisdorf D.J., Wingard J.R., Cutler C.S., Westervelt P., Woolfrey A., Couban S., Ehninger G., Johnston L., Maziarz R.T., Pulsipher M.A., Porter D.L., Mineishi S., McCarty J.M., Khan S.P., Anderlini P., Bensinger W.I., Leitman S.F., Rowley S.D., Bredeson C., Carter S.L., Horowitz M.M, & Confer D.L. (2012). Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. The New England journal of medicine, 367(16), 10.1056/NEJMoa1203517.

Publication 2012

BLOOD Blood Platelets Donors Grafts Immune Reconstitution Immunosuppression Infection Marrow Neutrophil Patients Relapse Transplantation Transplantation, Homologous

Optimizing Pediatric HIV Treatment

The Optimizing Pediatric HIV-1 (OPH) Treatment study ((NCT00428116) was an RCT in which HIV-infected infants who completed ≥2 years ART and attained immune reconstitution and normalized growth were randomized to TI or continued ART. Written informed consent was obtained from caregivers of children. The study received ethical approval from the Institutional Review Boards at the University of Washington and the Ethical Review Committee at Kenyatta National Hospital (KNH). An independent Data and Safety Monitoring Board (DSMB) reviewed the study at 6-monthly intervals.

Wamalwa D., Benki-Nugent S., Langat A., Tapia K., Ngugi E., Moraa H., Maleche-Obimbo E., Otieno V., Inwani I., Richardson B.A., Chohan B., Overbaugh J, & John-Stewart G.C. (2016). Treatment interruption after 2-year antiretroviral treatment (ART) initiated during acute/early HIV in infancy: a randomized trial. AIDS (London, England), 30(15), 2303-2313.

Publication 2016

Child Clinical Trials Data Monitoring Committees Ethics Committees, Research HIV-1 Immune Reconstitution Infant

Establishment of Humanized Mouse Model

Rag2^−/−γc^−/− mice were purchased from Taconic and maintained in the Laboratory Animal Unit, the University of Hong Kong. To establish humanized mice models, huPBMCs were isolated from buffy coat preparations of blood from healthy donors from the Hong Kong Red Cross. Vγ9Vδ2 T cell–depleted huPBMCs were obtained after depletion of Vδ2 T cells by magnetic microbeads (Miltenyi Biotec). 4–5-wk-old male or female Rag2^−/−γc^−/− mice were treated with liposomes (VU Medisch Centrum, Amsterdam, the Netherlands) 1 d before transplantation. The sublethally irradiated mice were transplanted i.p. with 30 × 10⁶ huPBMCs or Vγ9Vδ2 T cell–depleted huPBMCs. In general, huPBMCs from 1 buffy coat were used for generation of 8–10 humanized mice. After transplantation, graft-versus-host disease symptoms such as weight loss, temperature changes, and diarrhea were monitored daily. The immune reconstitution of humanized mice was examined at indicated times. All manipulations were performed in compliance with the approval of the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster and the guidelines for the use of experimental animals by the Committee on the Use of Live Animals in Teaching and Research, Hong Kong.

Tu W., Zheng J., Liu Y., Sia S.F., Liu M., Qin G., Ng I.H., Xiang Z., Lam K.T., Peiris J.S, & Lau Y.L. (2011). The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a γδ T cell population in humanized mice. The Journal of Experimental Medicine, 208(7), 1511-1522.

Publication 2011

Animals Animals, Laboratory Blood Buffy Coat Body Temperature Changes Diarrhea Donors Ethics Committees, Research Females Graft-vs-Host Disease Immune Reconstitution Liposomes Males Microspheres Mus RAG2 protein, human T-Lymphocyte Transplantation

Modulating Retinoid Signaling in Mice

C57BL/6J WT and Lck-Cre and LysM-Cre mice were obtained from Jackson Laboratories (Bar Harbor, ME). The dnRAR fl/fl mice (18 (link)) were a gift from Randolph J. Noelle (Dartmouth Medical School, Lebanon, NH). The dnRAR blocks retinoid signaling through all 3 RAR isoforms (19 (link)). dnRAR fl/fl cre^−/− (WT littermates) and dnRAR fl/fl cre +/– (T-dnRAR or LysM-dnRAR) were used for experiments. All mice were bred at the Pennsylvania State University (University Park, PA) according to university and IACUC guidelines. A+ and A– mice were generated by breeding C57BL/6J WT animals on lab prepared purified diets as described previously with and without retinyl acetate (25 μg/d) (4 (link)). A– mice were dosed with 37.5 μg of RA in small amounts of corn oil (10 μl) orally once at d7 post-infection (RA 1x), twice at d7 and d9 post-infection (RA 2x), or three times at d7, d9, and d11 post-infection (RA 3x). For some experiments A– mice were treated with RA three times weekly for 4 wk (metabolomics) or 8 wk (immune cell reconstitution). Serum retinol was quantified to verify the vitamin A status of experimental animals Supplementary Figure 1.

Snyder L.M., McDaniel K.L., Tian Y., Wei C.H., Kennett M.J., Patterson A.D., Ross A.C, & Cantorna M.T. (2019). Retinoic Acid Mediated Clearance of Citrobacter rodentium in Vitamin A Deficient Mice Requires CD11b+ and T Cells. Frontiers in Immunology, 9, 3090.

Full text: Click here

Publication 2018

All-Trans-Retinol Animals Cells Corn oil Diet Immune Reconstitution Infection Institutional Animal Care and Use Committees Mus Protein Isoforms Retinoids retinol acetate Serum Vitamin A

Most recents protocols related to «Immune Reconstitution»

Pediatric Immunohematology and Gene Therapy

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023

Adult Biological Assay Cells CYBB protein, human Immune Reconstitution NADPH Oxidase Patients Respiratory Burst Therapies, Biological Therapy, Gene

Humanized Immune System Engraftment in NRG Mice

NOD-Rag1null IL2rgnull (NRG) mice were obtained from Jackson Laboratories (Bar Harbor, Maine, USA). NRG pups (24–72 h old) were irradiated twice with 3 cGy 3 h apart and then engrafted intrahepatically with 10⁵–10⁶ CD34⁺ hematopoietic stem cells (HSC) isolated from human umbilical cord blood. At 12 weeks post engraftment, blood was collected to quantify human immune cell reconstitution using flow cytometry. Erythrocytes were lysed using an ACK lysis buffer and the remaining cells were treated with both anti-human Fc Receptor Binding Inhibitor and anti-mouse CD16/CD32 antibodies (eBiosciences). Cells were then stained with an antibody cocktail (mCD45-AlexaFluor 700 (1:50), hCD45-Pacific Blue (1:20), hCD3e-Qdot 605 (1:100), hCD4-PerCP-Cy5.5 (1:20), hCD8a-PE-Cy7 (1:20)), followed by fixable viability dye (APC-eFluor 780; eBiosciences). Samples were run on the Cytoflex LX flow cytometer equipped with a flow rate calibrator and analyzed using FlowJo software version 10 (Tree Star, Ashland, OR, USA). Mice with at least 10% or 50,000 per mL hCD45+ leukocytes in the blood were selected for subsequent experiments.

Afkhami S., D’Agostino M.R., Vaseghi-Shanjani M., Lepard M., Yang J.X., Lai R., Choi M.W., Chacon A., Zganiacz A., Franken K.L., Ertl H.C., Ottenhoff T.H., Jeyanathan M., Gillgrass A, & Xing Z. (2023). Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice. NPJ Vaccines, 8, 25.

Full text: Click here

Publication 2023

Anti-Antibodies BLOOD Buffers Cells Combined Antibody Therapeutics CY5.5 cyanine dye Erythrocytes Fc Receptor Flow Cytometry Homo sapiens Immune Reconstitution Leukocytes Mus Stem Cells, Hematopoietic Trees Umbilical Cord Blood

Allogeneic HSCT Outcomes Assessment

Primary end-points were the cumulative incidences of NRM and relapse (defined as disease recurrence according to marrow morphology, flow cytometry, cytogenetics, fluorescence in situ hybridization and polymerase chain reaction). Secondary end-points were: full donor-type engraftment, the cumulative incidences of grades ≥2 aGvHD and cGvHD, the probability of GvHD/relapse-free survival (GRFS) and CRFS. Immune reconstitution was monitored by means of T-cell counts and specific responses to pathogens. The method and evaluation of clones were described elsewhere [18 (link)].

Massei M.S., Capolsini I., Mastrodicasa E., Perruccio K., Arcioni F., Cerri C., Gurdo G., Sciabolacci S., Falzetti F., Zei T., Iacucci Ostini R., Brogna M., Panizza B.M., Saldi S., Merluzzi M., Tognellini R., Marchesi M., Minelli O., Aristei C., Velardi A., Pierini A., Ruggeri L., Martelli M.F., Carotti A, & Caniglia M. (2023). HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia. Bone Marrow Transplantation, 58(5), 526-533.

Publication 2023

Clone Cells Flow Cytometry Fluorescent in Situ Hybridization Immune Reconstitution Marrow pathogenesis Polymerase Chain Reaction Recurrence Relapse T-Lymphocyte Tissue Donors

Immune System Reconstitution Assay using Osteo-organoids

Immune system reconstitution assays were performed using the CD45.1/CD45.2 congenic system. Whole-marrow cells collected from two CD45.1⁺ osteo-organoids induced by a BMP-2–loaded scaffold for 3 months or two CD45.1⁺ femurs were transplanted into sublethally irradiated (5-Gy) CD45.2 recipients via retro-orbital sinus injection. The CD45.1/CD45.2 chimeric status of recipients’ PB was analyzed at 2, 4, 8, 12, and 16 weeks after transplantation.

Dai K., Zhang Q., Deng S., Yu Y., Zhu F., Zhang S., Pan Y., Long D., Wang J, & Liu C. (2023). A BMP-2–triggered in vivo osteo-organoid for cell therapy. Science Advances, 9(1), eadd1541.

Publication 2023

Biological Assay Bone Morphogenetic Protein 2 Cells Chimera Femur Immune Reconstitution Marrow Organoids Sinuses, Nasal Transplantation

Hematology Analysis for Immune Reconstitution

For the analysis of recipients’ hematology in immune system reconstitution assays, the PB of recipients from 0-Gy PBS treatment, 5-Gy PBS treatment, 5-Gy native BM treatment, and 5-Gy osteo-organoid treatment was collected by retro-orbital puncture at 2 days before and 2, 4, 8, 12, and 16 weeks after transplantation. All blood samples were analyzed within 2 hours using a Sysmex hematological analyzer (pocH-100i).

Dai K., Zhang Q., Deng S., Yu Y., Zhu F., Zhang S., Pan Y., Long D., Wang J, & Liu C. (2023). A BMP-2–triggered in vivo osteo-organoid for cell therapy. Science Advances, 9(1), eadd1541.

Publication 2023

Biological Assay BLOOD Immune Reconstitution Organoids Punctures Transplantation

Top products related to «Immune Reconstitution»

Facscanto 2 by BD

Sourced in United States, Germany, United Kingdom, Belgium, China, Australia, France, Japan, Italy, Spain, Switzerland, Canada, Uruguay, Netherlands, Czechia, Jersey, Brazil, Denmark, Singapore, Austria, India, Panama

The FACSCanto II is a flow cytometer instrument designed for multi-parameter analysis of single cells. It features a solid-state diode laser and up to four fluorescence detectors for simultaneous measurement of multiple cellular parameters.

Nod cg prkdcscid il2rgtm1wjl szj nsg by Jackson ImmunoResearch

Sourced in United States, Montenegro

The NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) is a genetically modified mouse strain. It is characterized by the absence of mature T cells, B cells, and natural killer cells, making it a useful model for research in immunology and oncology.

Nsg mice by Jackson ImmunoResearch

Sourced in United States, Montenegro

NSG mice are a strain of immunodeficient mice developed for use in biomedical research. They lack functional T cells, B cells, and natural killer cells, making them suitable for engraftment with human cells and tissues.

Facsdiva software by BD

Sourced in United States, Germany, United Kingdom, France, Canada, Belgium, Australia, Italy, Spain, Switzerland, China, Netherlands, Finland, Japan, Jersey, Lao People's Democratic Republic

FACSDiva software is a user-friendly flow cytometry analysis and data management platform. It provides intuitive tools for data acquisition, analysis, and reporting. The software enables researchers to efficiently process and interpret flow cytometry data.

Baytril by Bayer

Sourced in Germany, United States, United Kingdom, Italy, Belgium, France, Denmark, Canada, Japan, Brazil

Baytril is a veterinary antibiotic product produced by Bayer. It contains the active ingredient enrofloxacin, which is a fluoroquinolone antibiotic. Baytril is used to treat bacterial infections in animals.

Nod cg prkdcscid il2rgtm1wjl szj nsg mice by Jackson ImmunoResearch

Sourced in United States, Montenegro

The NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice are a strain of immunodeficient mice developed for use in biomedical research. They exhibit severe combined immunodeficiency and lack of mature T cells, B cells, and functional natural killer cells.

Hla a24 02 by STEMCELL

The HLA-A24:02 is a laboratory product used for research purposes. It is a recombinant protein that represents the HLA-A24:02 allele. The HLA-A24:02 allele is a common human leukocyte antigen (HLA) class I molecule. This product can be used in various immunological and cell biology studies.

Female blt nod scid il2rg nsg mice by Jackson ImmunoResearch

The Female BLT-NOD-scid IL2Rg−/− (NSG) mice are a type of immunodeficient mouse model. They have a deficiency in the interleukin-2 receptor gamma chain (IL2Rg), which leads to a lack of mature T cells, B cells, and natural killer cells. These mice are often used in biomedical research, particularly for the study of human immune system development and function.

Sas version 9 by SAS Institute

Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India

SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.

Facscanto 2 flow cytometer by BD

Sourced in United States, Germany, United Kingdom, Belgium, Japan, France, China, Australia, Italy, Spain, Canada, Switzerland, Sweden, Brazil, India, Mexico, Austria

The FACSCanto II is a flow cytometer manufactured by BD. It is a versatile instrument designed for multicolor flow cytometric analysis. The FACSCanto II can detect and analyze various properties of cells or particles suspended in a fluid as they flow through the system.

What is Immune Reconstitution and why is it important?

Immune Reconstitution is the process of restoring the immune system's functionality after depletion or dysfunction, often observed in conditions like HIV/AIDS, cancer treatments, or organ transplantation. This critical biological process involves the repopulation and reactivation of various immune cells, such as T cells, B cells, and natural killer cells, to re-establish the body's defense mechanisms. Understanding the mechanisms and dynamics of immune reconstitution is crucial for developing effective therapies and improving patient outcomes in a wide range of medical scenarios.

What are the different types or variations of Immune Reconstitution?

Immune Reconstitution can occur in different ways, depending on the underlying condition and medical intervention. For example, in the context of HIV/AIDS, immune reconstitution refers to the restoration of the immune system after the initiation of antiretroviral therapy. In cancer treatments, it involves the recovery of the immune system following chemotherapy or radiation therapy. In organ transplantation, immune reconstitution is essential for the recipient's body to accept the transplanted organ without rejection.

How can PubCompare.ai assist with Immune Reconstitution research?

PubCompare.ai allows researchers to screen protocol liteature more efficiently and leverage AI to pinpoint critical insights. The platform can help researchers identify the most effective protocols related to Immune Reconstitution for their specific research goals. PubCompare.ai's AI-driven analysis can highlight key differences in protocol effectiveness, enabling researchers to choose the best option for reproducibility and accuracy, thus accelerating discoveries and advancing the field of improving immune reconstitution.

What are some common challenges or considerations when working with Immune Reconstitution?

One of the key challenges in Immune Reconstitution is ensuring the proper balance between restoring immune function and preventing excessive inflammation or autoimmunity. Additionally, the timing and pace of immune reconstitution can vary greatly depending on the underlying condition and the specific therapies used. Researchers must also consider the potential impact of comorbidities, genetic factors, and individual patient variability on the immune reconstitution process. By leveraging the advanced tools provided by PubCompare.ai, researchers can more efficiently navigate these complexities and identify the optimal research protocols and products to address these challanges.

How can PubCompare.ai help researchers optimize their Immune Reconstitution research?

PubCompare.ai's AI-powered tools can streamline the process of identifying the most effective protocols and products for Immune Reconstitution research. The platform's advanced search and comparison capabilities allow researchers to quickly sift through the vast amount of available literature, pre-prints, and patents to pinpoint the most relevant and impactful studies. By leveraging artificial intelligence, PubCompare.ai can highlight the key differences in protocol effectiveness, enabling researchers to make informed decisions and choose the best options for their specific research goals. This can significantly accelerate discoveries and advance the field of improving immune reconstitution.

More about "Immune Reconstitution"

Immune reconstitution is the process of restoring the functionality of the immune system after depletion or dysfunction, often observed in conditions like HIV/AIDS, cancer treatments, or organ transplantation.
This critical biological process involves the repopulation and reactivation of various immune cells, such as T cells, B cells, and natural killer (NK) cells, to re-establish the body's defense mechanisms.
Understanding the mechanisms and dynamics of immune reconstitution is crucial for developing effective therapies and improving patient outcomes in a wide range of medical scenarios.
Researchers can leverage advanced AI-powered tools, like those offered by PubCompare.ai, to streamline their quest for the optimal research protocols and products, accelerating discoveries and advancing the field of improving immune reconstitution.
These tools can help identify the best protocols from literature, pre-prints, and patents, utilizing techniques like flow cytometry (e.g., FACSCanto II, FACSDiva software) and animal models (e.g., NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, Female BLT-NOD-scid IL2Rg−/− (NSG) mice).
Additionally, researchers can explore the use of pharmaceuticals, such as Baytril, to support immune reconstitution in various medical conditions.
The HLA-A24:02 allele has also been associated with improved immune reconstitution in some cases.
By leveraging the latest advancements in AI-powered research tools and incorporating a holistic understanding of immune reconstitution, scientists can accelerate their discoveries and develop more effective therapies to improve patient outcomes across a range of medical scenarios.
The SAS version 9.4 statistical software can also be utilized for data analysis to support these research efforts.